Combined therapy targeting AR and EZH2 curbs castration-resistant prostate cancer enhancing anti-tumor T-cell response.
Saved in:
| Title: | Combined therapy targeting AR and EZH2 curbs castration-resistant prostate cancer enhancing anti-tumor T-cell response. |
|---|---|
| Authors: | Fischetti I; Molecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy., Botti L; Molecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy., Sulsenti R; Molecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy., Cancila V; Tumor Immunology Unit, Department of Health Sciences, University of Palermo, Italy., Enriquez C; Molecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy., Ferri R; Molecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy., Bregni M; ASST Valle Olona, Busto Arsizio, Italy., Crivelli F; Anatomia Patologica, ASST Valle Olona, Busto Arsizio, Italy., Tripodo C; Tumor Immunology Unit, Department of Health Sciences, University of Palermo, Italy., Colombo MP; Molecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy., Jachetti E; Molecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy. |
| Source: | Epigenomics [Epigenomics] 2024 Mar 26. Date of Electronic Publication: 2024 Mar 26. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101519720 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1750-192X (Electronic) Linking ISSN: 1750192X NLM ISO Abbreviation: Epigenomics Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
